Chemical Structure : ADT-1004
Catalog No.: PC-23212Not For Human Use, Lab Use Only.
ADT-1004 is an orally bioavailable prodrug of ADT-007, potent, selective pan-RAS inhibitor, selectively inhibits PDAC cells with mutant KRAS, does not impact the growth of tumors from RAS WT PDAC cells.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
ADT-1004 is an orally bioavailable prodrug of ADT-007, potent, selective pan-RAS inhibitor, selectively inhibits PDAC cells with mutant KRAS, does not impact the growth of tumors from RAS WT PDAC cells.
ADT-1004 is designed to improve the water solubility and metabolic stability of ADT-007.
ADT-1004 inhibited ERK phosphorylation in PDAC tumors.
ADT-1004 blocked tumor growth and ERK phosphorylation in PDX PDAC models with KRAS G12D , KRAS G12V , KRAS G12C , or KRAS G13Q mutations.
ADT-1004 treatment increased CD4 + and CD8 + T cells in the TME consistent with exhaustion and increased MHCII + M1 macrophage and dendritic cells
ADT-1004 demonstrated superior efficacy over sotorasib and adagrasib in tumor models involving human PDAC cells resistant to these KRAS G12C inhibitors.
M.Wt | 589.66 | |
Formula | C33H36FN3O6 | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
1. Reddy Bandi DS, et al. bioRxiv [Preprint]. 2024 Oct 8:2024.10.04.616725.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright